Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 25, 2019, to announce its financial results for the second quarter of 2019. The filing primarily directs investors to an accompanying press release (Exhibit 99.1) and supplemental information on the company's website (Exhibit 99.2) for detailed financial performance and operational updates. Investors should review these attached documents for specific figures regarding revenue, earnings, and any forward-looking statements made by the company. This 8-K serves as a notification of the Q2 2019 earnings release. While the 8-K itself does not contain the financial details, it is the official channel through which the company disseminates this crucial information to the market. Therefore, the key takeaways for investors will be found within the referenced press release and supplemental materials, which would have been made available concurrently with this filing.
Key Highlights
- 1Bristol-Myers Squibb announced its Q2 2019 financial results via a press release filed on July 25, 2019.
- 2The 8-K filing serves as an official notification of the earnings release.
- 3Detailed financial results and operational updates are contained within Exhibit 99.1 (Press Release) and Exhibit 99.2 (Supplemental Information).
- 4Investors are directed to the company's website (www.bms.com) for supplemental financial data.
- 5The filing is primarily informational, pointing investors to the furnished exhibits for substantive content.